Espeland M et al. Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention. Diabetes Care 2016;39:764-771. doi: 10.2337/dc15-2230 Le diabète de type 2 (DT2) peut avoir des effets délétères sur le cerveau, en lien avec l’insulinorésistance cérébrale, les alternances d’hypo- et d’hyperglycémies, et avec les facteurs indirects […]
Farr OM, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia May;59(5):954-65. Epub 2016 Feb 1. doi: 10.1007/s00125-016-3874-y Le diabète de type 2 […]
Natovich R, et al. Cognitive Dysfunction: Part and Parcel of the Diabetic Foot. Diabetes Care 2016 May (ahead of print). doi: 10.2337/dc15-2838 Le « pied diabétique » est une complication fréquente et sévère, responsable d’un taux élevé d’amputation et de complications infectieuses et associée à un risque élevé de mortalité [1]. En […]
Andersson, et al. Left ventricular remodelling changes without concomitant loss of myocardial fat after long-term dietary intervention. Int J Cardiol. 2016 Apr 22;216:92-96. doi: 10.1016/j.ijcard.2016.04.050 L’obésité est associée à des modifications structurelles et fonctionnelles du cœur et notamment du myocarde, telles une surcharge volumique, une augmentation du pouls, de la pression artérielle, et […]
DCCT/EDIC Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016 Feb 9. pii: dc151990. [Epub ahead of print]. doi: 10.2337/dc15-1990 The ACCORD study group writing committee. 9-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care. 2016 Jan […]
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 2016 Apr 2. 387(10026):1377-96. doi: 10.1016/S0140-6736(16)30054-X NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies […]
Tuccori M, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016 Mar 30;(352):i1541. doi: 10.1136/bmj.i1541 Nous avions rapporté le mois dernier, dans cette même édition, des résultats très encourageants d’un essai clinique randomisé testant la pioglitazone (PIO) en terme de protection cardiovasculaire secondaire chez des patients insulinorésistants […]
Dewey FE, et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016 Mar 24;374(12):1123-33. doi: 10.1056/NEJMoa1510926 Le taux plasmatique de triglycérides (TG) est en partie génétiquement déterminé et des taux élevés de TG plasmatiques ont été associés à une augmentation du risque cardiovasculaire. Des mutations inactivatrices […]
Kernan et al. Pioglitazone after ischemic stroke or transient ischemic attack. New Engl J Med 2016 [Epub Ahead of Print]. doi: 10.1056/NEJMoa1506930 Les accidents vasculaires cérébraux constitués (AVC) et les accidents ischémiques transitoires (AIT) concernent 14 millions de patients par an à travers le monde et représentent un problème majeur de santé publique, […]
Carstensen B, et al. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. [Epub ahead of print 2016 Feb 29]. doi: 10.1007/s00125-016-3884-9 Il est habituellement reconnu que les patients avec un diabète ont une incidence des cancers approximativement 20 à 25 % plus […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
